Drugs / multi-epitope melanoma peptide vaccine
multi-epitope melanoma peptide vaccine
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00705640 | May 2008 → Jun 2009 | conjunctival cancer, cutaneous melanoma, ocular melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 1 | NCT00118313 | Nov 2004 → Jul 2006 | cutaneous melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00118274 | Mar 2005 → Feb 2010 | cutaneous melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00071981 | May 2005 → Aug 2011 | cutaneous melanoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00085189 | May 2004 → Sep 2007 | iris melanoma, medium/large size posterior uveal melanoma, mucosal melanoma, ocular melanoma with extraocular extension +1 | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT00089193 | Sep 2003 → Feb 2007 | cutaneous melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 2 | NCT00089206 | Aug 2002 → Nov 2005 | cutaneous melanoma, ocular melanoma | University of Virginia | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | multi-epitope melanoma peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00089206 ↗ |
| Known as | 12MP | “Patients were vaccinated with 12 class I major histocompatibility complex-restricted melanoma peptides (12MP) to stimulate CD8(+) T cells” PMID 21690475 ↗ Jun 2011 |
| Known as | MELITAC 12.1 | “immunized with multiple melanoma peptides (MELITAC 12.1) in adjuvants comprising IFA and/or the TLR3-agonist pICLC” PMID 32350119 ↗ Apr 2020 |
| Modality | Vaccine | “multi-epitope peptide vaccine comprising 12 melanoma peptides restricted by Class I MHC (12MP)” NCT00071981 ↗ |
| Route | Subcutaneous | “a single subcutaneous/intradermal administration of peptide vaccine in Montanide adjuvant” PMID 24377099 ↗ Nov 2013 |